Gilead continues support for Global COVID-19 Response with Remdesivir Donations
Gilead Sciences,a biopharmaceutical company dedicated to advancing innovative medicines,continues to play a role in the global fight against COVID-19 through ongoing support for access to its antiviral treatment,Veklury (remdesivir).
Data from clinical trials indicate that Veklury does not appear to pose a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes when administered during the second and third trimesters of pregnancy. However,there is currently insufficient data to assess risks associated with first-trimester exposure. Given the risks associated with untreated COVID-19 during pregnancy, treatment decisions should be made in consultation with healthcare professionals.
Veklury can be present in breast milk. Healthcare providers and breastfeeding individuals should consider the developmental and health benefits of breastfeeding alongside the mother’s clinical need for Veklury and potential effects on the infant. Breastfeeding individuals diagnosed with COVID-19 should adhere to clinical guidelines to minimize the risk of transmission to their infants.
Gilead sciences, operating in over 35 countries with headquarters in Foster City, California, has a three-decade history of breakthroughs in medicine, focusing on life-threatening diseases including HIV, viral hepatitis, cancer, and inflammation. The company remains committed to preventing and treating these conditions, including ongoing efforts related to COVID-19.
The company acknowledges that future results are subject to risks and uncertainties, including its ability to manage remdesivir supply and distribution, the progress and outcomes of clinical trials, and other factors detailed in its filings with the U.S. Securities and Exchange Commission (specifically, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025).
Further information, including the full U.S. Prescribing Information for Veklury, is available at www.gilead.com. Follow Gilead on X/Twitter (@gilead Sciences) and LinkedIn (@Gilead-Sciences) for updates.
Veklury, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
